NOV 02, 2020 7:00 AM PST

New Cancer Drug Reboots Stalled Immunotherapies

WRITTEN BY: Tara Fernandez


In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumor cells. The hope is that these types of treatments will be more effective at permanently eliminating cancer cells and have fewer side effects due to their more targeted nature. However, clinical testing of immunotherapeutics has revealed that certain types of malignancies are resistant to immunotherapies.

Cancer researchers have developed a new drug to kickstart the immune system in patients with cancers that are unresponsive to immunotherapies. A study published in the Proceedings of the National Academy of Sciences details data from a clinical trial of plerixafor in patients with advanced pancreatic or colorectal cancer. The aim of the study was to evaluate the potential of the drug in enhancing the performance of a class of immunotherapies known as immune checkpoint inhibitors. Such treatments unleash the body’s immune system by lifting inbuilt safety nets, activating immune cells to aggressively target and remove tumors.

"Those tumors often do not seem to be visible to the immune system and do not seem to be unmasked by these therapies that are currently available,” explained Tobias Janowitz, a lead author of the study. “And we have reasons to believe that that is because they can engage an immune suppressive pathway that keeps most of the immune cells out of the cancer cell nest."

Analysis of the patient samples revealed that their tumors had been infiltrated by immune cells after receiving plerixafor — a critical first step required for effective immunotherapies. The team was encouraged by additional data that showed plerixafor was also able to help patients whose cancers do respond to checkpoint inhibitors, demonstrating its potential versatility in the clinic.

"I am delighted that the work of this multi-disciplinary team has translated important laboratory findings into patients, with the potential to make a difference in these hard-to-treat cancers," said Duncan Jodrell who led the clinical trial.

Sources: PNAS, Medical Xpress.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 22, 2020
Immunology
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
OCT 22, 2020
Migraines: Dark Times and (Pharmaceutical) Rays of Hope
Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more pr ...
NOV 12, 2020
Immunology
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
NOV 12, 2020
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
Nutrition is essential to health; what we eat in our daily diet affects our overall health condition and what diseases w ...
NOV 16, 2020
Immunology
Australian COVID-19 vaccine is promising and could be released next year
NOV 16, 2020
Australian COVID-19 vaccine is promising and could be released next year
Pharmaceutical companies worldwide are racing to develop a COVID-19 vaccine that will hopefully end this pandemic and he ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
FEB 25, 2021
Immunology
Two Immune Guardians of the Brain Discovered
FEB 25, 2021
Two Immune Guardians of the Brain Discovered
Most organ systems are protected by a cavalry of immune cells present in the circulation—but not the brain. Consid ...
Loading Comments...